Nymox Pharmaceutical has announced the Immunogenicity results for its drug candidate NX-1207 BPH Program, which has not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug.
NX-1207 is in late stage Phase 3 development in the US for the treatment of benign prostatic hyperplasia (BPH), a common condition of older men associated with growth in prostate size as men age.
The company said the extensive clinical immunogenicity testing of men in its pivotal Phase 3 trials (NX02-0017 and NX02-0018) and Phase 3 repeat injection safety study (NX02-0020) showed no evidence of antidrug antibody formation.
Periodic safety monitoring reviews of the NX-1207 trials till date have shown no evidence of any allergic reaction to the drug either on first injection or repeat injection.
The company revealed that it will present more detailed scientific information from the studies at upcoming medical conferences.
NX-1207 is also being evaluated for the treatment of low risk localized prostate cancer where NX-1207 is administered directly into the area of the prostate where the cancer was detected.